3 completed, 1 not yet recruiting. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 3, Not yet recruiting 1 |
Follow Qsymia: new trials by email Literature Review of Qsymia trials Research Report on Qsymia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Weight Gain Prevention in Adolescents and Young Adults Qsymia 7.5 miligrams (mg)-46 mg Extended Release Capsule, Placebo - Healthy Volunteers | Phase 3 | Not yet recruiting | University of Minnesota | 140 | 2026-11-01 | 2026-06-04 |
| Individualized Obesity Pharmacotherapy Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion - Obesity | Phase 3 | Completed | Mayo Clinic | 193 | 2017-12-11 | 2023-07-18 |
| EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) Exenatide once weekly (EQW ), Dapagliflozin (DAPA), EQW plus DAPA - Polycystic Ovary Syndrome, Obesity | Phase 3 | Completed | Woman's | 119 | 2016-03-22 | 2021-01-29 |
| A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787) VI-0521, Placebo - Obesity | Phase 3 | Completed | VIVUS LLC | 676 | 2008-12-01 | 2012-09-10 |
Obesity (3) · Polycystic Ovary Syndrome (1)
Mayo Clinic (1) · University of Minnesota (1) · VIVUS LLC (1) · Woman's (1)
United States (2)
Aaron Kelly, PhD (1) · Andres J Acosta (1) · Craig Peterson (1) · Drake Bellanger, MD (1) · Karen Elkind-Hirsch, PhD (1)